卡瑞利珠单抗联合或不联合转移灶导向立体定向体部放疗治疗复发或转移性鼻咽癌的随机多中心2期试验
这项在中国3个中心开展的随机对照2期试验纳入39例复发或转移性鼻咽癌患者,按1:1随机接受卡瑞利珠单抗单药(20例)或卡瑞利珠单抗联合转移灶导向立体定向体部放疗(19例)。主要终点未照射病灶的客观缓解率在两组间无显著差异(联合组26.3% vs 单药组30.0%,P=1.0),研究未达到主要终点。
要点
- 联合组与单药组未照射病灶客观缓解率分别为26.3%和30.0%,差异无统计学意义(P=1.0)。
- 中位随访25.8个月,联合组与单药组中位无进展生存期分别为9.3个月和8.8个月(P=.750)。
- 探索性分析提示在病灶数>3个的患者中联合组总生存期更长(HR 0.23,95%CI 0.07-0.77,P=.009)。
核心结论
- 在复发或转移性鼻咽癌患者中,卡瑞利珠单抗联合转移灶导向立体定向体部放疗未达到主要终点,即未改善未照射病灶的客观缓解率。
研究设计与样本
- 随机、对照、多中心2期试验,在中国3个中心开展(NCT04830267)。
- 纳入既往未接受免疫治疗、病灶数≥2个且至少1个可测量病灶的复发或转移性鼻咽癌患者,按1:1随机分配至卡瑞利珠单抗单药组(20例)或卡瑞利珠单抗联合转移灶导向立体定向体部放疗组(19例)。
- 联合组要求有1个适合立体定向体部放疗的病灶,处方剂量为27 Gy分3次,隔日照射。
- 主要终点为采用实体瘤疗效评价标准v1.1评估的未照射病灶客观缓解率。
主要发现
- 2021年4月至2023年8月共随机分配39例患者,其中17/39(43.6%)为寡转移性疾病(≤3个病灶),18/39(46.2%)有肝脏受累,3/39(7.7%)为局部区域复发。
- 未照射病灶客观缓解率联合组为26.3%,单药组为30.0%,差异无统计学意义(P=1.0)。
- 未照射病灶疾病控制率联合组为73.7%,单药组为60.0%(P=.571)。
- 中位随访25.8个月,联合组中位无进展生存期为9.3个月(95%CI 6.2-未达到),单药组为8.8个月(95%CI 3.3-未达到)(P=.750)。
- 探索性分析提示在病灶数>3个的患者中,联合组总生存期更长(HR 0.23,95%CI 0.07-0.77,P=.009)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the efficacy of metastasis-directed therapy (MDT) when added to camrelizumab (Cam) in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC). METHODS AND MATERIALS: We conducted a randomized, controlled, multicenter, phase 2 trial in 3 centers from China (NCT04830267). Patients with R/M-NPC, without prior exposure to immunotherapy, who presented with ≥2 lesions, and at least 1 measurable lesion were randomized 1:1 to either Cam alone or Cam plus MDT (Cam+MDT). Patients randomized to the MDT group must have 1 lesion that is amendable to stereotactic body radiation therapy (SBRT) prescribed to 27 Gy in 3 fractions every other day. The primary endpoint was objective response rate (ORR) of unirradiated lesions using Response Evaluation Criteria in Solid Tumors v1.1. RESULTS: Between April 2021 and August 2023, 39 patients were randomly assigned to receive either Cam (n = 20) or Cam+MDT (n = 19). In total, 17 out of 39 (43.6%) patients had oligometastatic disease (≤3 lesions), 18 out of 39 (46.2%) had liver involvement, and 3 out of 39 (7.7%) had locoregional recurrent disease. ORR of unirradiated lesions did not differ between the treatment groups (26.3% [Cam+MDT] vs 30.0% [Cam], P = 1.0). The disease control rate of unirradiated lesions was 73.7% in the Cam+MDT group compared with 60.0% in the Cam group (P = .571). After a median follow-up of 25.8 months, median progression-free survival was 9.3 (95% CI, 6.2-not reached [NR]) months in the Cam+MDT group and 8.8 (95% CI, 3.3-NR) months in the Cam group (P = .750). Exploratory analyses suggested a longer overall survival (OS) with Cam+MDT for patients with >3 lesions (HR, 0.23; 95% CI, 0.07-0.77; P = .009). G3 and above adverse events were comparable between the treatment groups (15.8% [Cam+MDT] vs 20.0% [Cam]). The overall rate of capillary proliferation was 17.9% (7/39) for the trial. CONCLUSIONS: Our study did not meet its primary endpoint of superior ORR of unirradiated lesions with the addition of MDT to Cam in patients with R/M-NPC.
引用
- Zhang X, Yan J, Lei Q, et al. A Randomized, Multicenter, Phase 2 Trial of Camrelizumab With or Without Metastasis-directed Stereotactic Body Radiation Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2024. PMID: 39454735. doi:10.1016/j.ijrobp.2024.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。